Picture of Mesa Laboratories logo

MLAB — Mesa Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Mesa Laboratories To Record Non-Cash Impairment Losses Related To Clinical Genomics & Biopharmaceutical Development Units Of $271 Million In Q4 Of 2024

April 2 (Reuters) - Mesa Laboratories Inc  MLAB.O :
    * MESA LABORATORIES: TO RECORD NON-CASH IMPAIRMENT LOSSES
RELATED
TO CLINICAL GENOMICS & BIOPHARMACEUTICAL DEVELOPMENT UNITS OF
$271 MILLION IN Q4 OF 2024
    * MESA LABORATORIES INC: EXPECT UNAUDITED RESULTS FOR Q4 OF
2024
WILL INCLUDE NON-CASH IMPAIRMENT LOSSES OF ABOUT$123 MILLION
RELATED TO GOODWILL
    * MESA LABORATORIES INC: EXPECT TO RECORD NON-CASH
IMPAIRMENT
LOSSES TO OTHER INTANGIBLE ASSETS OF ABOUT $148 MILLION
    * MESA LABORATORIES INC: NON-CASH ACCOUNTING CHARGES ARE NOT
EXPECTED TO IMPACT CASH FLOWS FROM CURRENT OR FUTURE OPERATIONS

Source text for Eikon:  ID:n0001437749-24-010537 
Further company coverage:  MLAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Mesa Laboratories

See all news